secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001493152-22-022067
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q2 2022 revenue $5.0M, down 82% YoY; net loss $2.7M
------------------------------------------------------------------

- Revenue of $5.0M vs $27.4M a year ago; gross profit margin 81.8% due to sales volume inefficiencies.
- Net loss of $2.7M ($0.08 loss per diluted share) compared to net income of $9.8M in Q2 2021.
- Operating loss of $4.1M vs operating income of $11.8M; adjusted EBITDA loss $2.3M.
- Cash, equivalents, and marketable securities at $96.0M as of June 30, 2022.
- Business highlights: Indian JV CoSara cleared for Hepatitis C test; monkeypox test reagents shipped; Co-Dx PCR Home platform optimization continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/0001493152-22-022067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer